These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33723724)

  • 1. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
    Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC
    Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
    Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
    Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
    Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
    Myers AP; Konstantinopoulos PA; Barry WT; Luo W; Broaddus RR; Makker V; Drapkin R; Liu J; Doyle A; Horowitz NS; Meric-Bernstam F; Birrer M; Aghajanian C; Coleman RL; Mills GB; Cantley LC; Matulonis UA; Westin SN
    Int J Cancer; 2020 Jul; 147(2):413-422. PubMed ID: 31714586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
    Garcia-Carracedo D; Chen ZM; Qiu W; Huang AS; Tang SM; Hruban RH; Su GH
    Pancreas; 2014 Mar; 43(2):245-9. PubMed ID: 24518503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of TAS-117 in patients with advanced solid tumors harboring germline
    Rodón J; Funchain P; Laetsch TW; Arkenau HT; Hervieu A; Singer CF; Murciano-Goroff YR; Chawla SP; Anthony K; Yamamiya I; Liu M; Halim AB; Benhadji KA; Takahashi O; Delaloge S
    Future Oncol; 2022 Sep; 18(30):3377-3387. PubMed ID: 36039910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
    Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
    Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
    Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
    Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
    Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
    Doi T; Takahashi S; Aoki D; Yonemori K; Hara H; Hasegawa K; Takehara K; Harano K; Yunokawa M; Nomura H; Shimoi T; Horie K; Ogasawara A; Okame S
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):605-616. PubMed ID: 38411735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
    Kalinsky K; Hong F; McCourt CK; Sachdev JC; Mitchell EP; Zwiebel JA; Doyle LA; McShane LM; Li S; Gray RJ; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; O'Dwyer PJ; Harris LN; Arteaga CL; Chen AP; Flaherty KT
    JAMA Oncol; 2021 Feb; 7(2):271-278. PubMed ID: 33377972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.